Now showing items 1-8 of 8

    • Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. 

      Ragulan, C; Eason, K; Fontana, E; Nyamundanda, G; Tarazona, N; Patil, Y; Poudel, P; Lawlor, RT; Del Rio, M; Koo, S-L; Tan, W-S; Sclafani, F; Begum, R; Teixeira Mendes, LS; Martineau, P; Scarpa, A; Cervantes, A; Tan, IB; Cunningham, D; Sadanandam, A (2019-05-21)
      Previously, we classified colorectal cancers (CRCs) into five CRCAssigner (CRCA) subtypes with different prognoses and potential treatment responses, later consolidated into four consensus molecular subtypes (CMS). Here ...
    • Applications of intertumoural, intratumoural and intermolecular heterogeneity for personalised medicine in colorectal cancer 

      Eason, K (2020-03-31)
      Colorectal cancer (CRC) is a heterogeneous disease, both at the molecular level and in the context of patients' responses to treatment. Few biomarkers are currently in place that can help to stratify patients in the clinical ...
    • Benefit from anti-EGFRs in <i>RAS</i> and <i>BRAF</i> wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. 

      Cremolini, C; Benelli, M; Fontana, E; Pagani, F; Rossini, D; Fucà, G; Busico, A; Conca, E; Di Donato, S; Loupakis, F; Schirripa, M; Lonardi, S; Borelli, B; Ongaro, E; Eason, K; Morano, F; Casagrande, M; Fassan, M; Sadanandam, A; de Braud, F; Falcone, A; Pietrantonio, F (2019-01)
      <h4>Objective</h4>Primary tumour location is regarded as a reliable surrogate of colorectal cancer biology. Sensitivity to anti-EGFRs (Epidermal Growth Factor Receptor) of metastatic transverse colon cancers (mTCCs) has ...
    • Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. 

      Fontana, E; Eason, K; Cervantes, A; Salazar, R; Sadanandam, A (2019-04)
      The Colorectal Cancer Subtyping Consortium identified four gene expression consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal), using multiple microarray or RNA-sequencing ...
    • Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity. 

      Heindl, A; Khan, AM; Rodrigues, DN; Eason, K; Sadanandam, A; Orbegoso, C; Punta, M; Sottoriva, A; Lise, S; Banerjee, S; Yuan, Y (2018-09-25)
      How tumor microenvironmental forces shape plasticity of cancer cell morphology is poorly understood. Here, we conduct automated histology image and spatial statistical analyses in 514 high grade serous ovarian samples to ...
    • Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes? 

      Eason, K; Sadanandam, A (2016-09)
      Tumor heterogeneity is reflected and influenced by genetic, epigenetic, and metabolic differences in cancer cells and their interactions with a complex microenvironment. This heterogeneity has resulted in the stratification ...
    • Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. 

      Vlachogiannis, G; Hedayat, S; Vatsiou, A; Jamin, Y; Fernández-Mateos, J; Khan, K; Lampis, A; Eason, K; Huntingford, I; Burke, R; Rata, M; Koh, D-M; Tunariu, N; Collins, D; Hulkki-Wilson, S; Ragulan, C; Spiteri, I; Moorcraft, SY; Chau, I; Rao, S; Watkins, D; Fotiadis, N; Bali, M; Darvish-Damavandi, M; Lote, H; Eltahir, Z; Smyth, EC; Begum, R; Clarke, PA; Hahne, JC; Dowsett, M; de Bono, J; Workman, P; Sadanandam, A; Fassan, M; Sansom, OJ; Eccles, S; Starling, N; Braconi, C; Sottoriva, A; Robinson, SP; Cunningham, D; Valeri, N (2018-02)
      Patient-derived organoids (PDOs) have recently emerged as robust preclinical models; however, their potential to predict clinical outcomes in patients has remained unclear. We report on a living biobank of PDOs from ...
    • Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. 

      Wagner, S; Vlachogiannis, G; De Haven Brandon, A; Valenti, M; Box, G; Jenkins, L; Mancusi, C; Self, A; Manodoro, F; Assiotis, I; Robinson, P; Chauhan, R; Rust, AG; Matthews, N; Eason, K; Khan, K; Starling, N; Cunningham, D; Sadanandam, A; Isacke, CM; Kirkin, V; Valeri, N; Whittaker, SR (2019-03)
      Despite showing clinical activity in BRAF-mutant melanoma, the MEK inhibitor (MEKi) trametinib has failed to show clinical benefit in KRAS-mutant colorectal cancer. To identify mechanisms of resistance to MEKi, we employed ...